ClinicalTrials.gg
CompletedNCT04541043Nefigard-OLEUpdated Feb 10, 2025Results posted

Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

A Phase 3 interventional study of Nefecon 16mg daily in Primary IgA Nephropathy, sponsored by Calliditas Therapeutics AB. Completed at 18 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Calliditas Therapeutics AB · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
24th of 67
119 · median 67
Started
2020
with 2 others
Phase 3
21 of 73
8 open now
Registered
26th of 73
by date
Lead sponsor
3 of 73
Calliditas Therapeutics AB

Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 24th largest by enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2020, is one of 21 in phase 3, and was the 26th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon.

Read the detailed description

This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon. During Study Nef-301 OLE, the patients and Investigators will remain blinded to treatment given in Study Nef-301.

During Study Nef-301 OLE, patients will receive Nefecon for a 9-month period. The dose may be reduced if clinically relevant adverse events (AEs) develop during the 9-month Treatment Period that the Investigator considers related to the study drug and that mandate dose reduction.

Patients will remain on a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) throughout the study. The patient will come for a follow-up visit at 12 months after first dose.

03

Conditions studied

  • Primary IgA Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients that completed study Nef-301
  2. On a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) at the maximum allowed dose or maximum tolerated dose according to the 2012 KDIGO guidelines
  3. Willing and able to provide written .
  4. UPCR equal to or more than 0.8 g/gram
  5. equal to or more than 30 mL/min per 1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

Exclusion criteria

Exclusion Criteria:

  1. Systemic diseases that may cause mesangial IgA deposition.
  2. Patients who have undergone a kidney transplant;
  3. Patients with presence of other glomerulopathies and/or nephrotic syndrome
  4. Patients with acute, chronic, or latent infectious disease including hepatitis, tuberculosis (TB), (HIV), and chronic urinary tract infections;
  5. Patients with liver cirrhosis, as assessed by the Investigator;
  6. Patients with a diagnosis of type 1 or type 2 diabetes mellitus which is poorly controlled
  7. Patients with history of unstable angina, class III or IV congestive heart failure, and/or arrhythmia, as judged by the Investigator;
  8. Patients with unacceptable blood pressure control defined as a blood pressure consistently above national guidelines for proteinuric renal disease, as assessed by the Investigator.
  9. Patients with diagnosed within the past 5 years.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Active Nefecon treatment

    Nefecon 16 mg once daily by mouth for 9 months

    Drug: Nefecon 16mg daily

Interventions

  • DrugNefecon 16mg daily

    All study patients received Nefecon 16 mg daily for 9 months.

06

What researchers measure

Primary outcomes

  1. Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline

    The outcome is measured as UPCR based on 24 hour urine collections at 9 months following the first dose of Nefecon compared to baseline Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram

    Time frame: 9 months

  2. Ratio of Estimated Glomerular Filtration Rate (eGFR) at 9 Months Compared to Baseline

    The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 9 months following the first dose of Nefecon compared to baseline. I.e. eGFR at 9 months divided by eGFR at Baseline.

    Time frame: 9 months

Secondary outcomes

  1. Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months Compared to Baseline

    Ratio of urine albumin to creatinine ratio (UACR) measured by 24h urine sampling at 9 months compared to baseline. I.e. UACR at 9 months divided by eGFR at Baseline.

    Time frame: 9 months

  2. Change From Baseline Short Form 36 (SF-36) Quality of Life Assessment at 12 Months

    Short Form 36 (SF-36) quality of life assessment at 12 months compared to baseline, i.e. change from baseline. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved, i.e. 0 is the minimum and 100 is the maximum score.

    Time frame: Baseline & 12 months

  3. Number of Patients With Microhematuria at 9 Months Compared to Baseline

    Time frame: 9 months

  4. Number of Patients Receiving Rescue Treatment

    Systemic immunosuppressive drugs (including glucocorticoids in some situations ), dialysis, and renal transplantation are considered as rescue medications in this study.

    Time frame: 12 months

  5. Proportion of Patients on Dialysis, Undergoing Kidney Transplantation, or With eGFR <15 mL/Min Per 1.73 m2

    Looking at number of patients with end stage kidney disease defined as being on dialysis, undergoing kidney transplantation, or having eGFR \<15 mL/min per 1.73 m2

    Time frame: 12 months

  6. Change From Baseline Cortisol Suppression at 9 Months

    Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.

    Time frame: Baseline & 9 months

  7. Change From Baseline Cortisol Suppression at 12 Months

    Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.

    Time frame: Baseline & 12 months

07

Results

Posted Jan 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Started4574
Completed4362
Not completed212

Outcome measures

PrimaryRatio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline

The outcome is measured as UPCR based on 24 hour urine collections at 9 months following the first dose of Nefecon compared to baseline Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram

Time frame:
9 months
Reported as:
Geometric least squares mean · ratio
Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline
ratioRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline0.67 (0.56 to 0.80)0.69 (0.60 to 0.80)
PrimaryRatio of Estimated Glomerular Filtration Rate (eGFR) at 9 Months Compared to Baseline

The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 9 months following the first dose of Nefecon compared to baseline. I.e. eGFR at 9 months divided by eGFR at Baseline.

Time frame:
9 months
Reported as:
Geometric least squares mean · ratio
Ratio of Estimated Glomerular Filtration Rate (eGFR) at 9 Months Compared to Baseline
ratioRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Ratio of Estimated Glomerular Filtration Rate (eGFR) at 9 Months Compared to Baseline0.97 (0.94 to 1.01)0.97 (0.94 to 1.00)
SecondaryRatio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months Compared to Baseline

Ratio of urine albumin to creatinine ratio (UACR) measured by 24h urine sampling at 9 months compared to baseline. I.e. UACR at 9 months divided by eGFR at Baseline.

Time frame:
9 months
Reported as:
Geometric least squares mean · ratio
Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months Compared to Baseline
ratioRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months Compared to Baseline0.60 (0.49 to 0.75)0.65 (0.55 to 0.77)
SecondaryChange From Baseline Short Form 36 (SF-36) Quality of Life Assessment at 12 Months

Short Form 36 (SF-36) quality of life assessment at 12 months compared to baseline, i.e. change from baseline. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved, i.e. 0 is the minimum and 100 is the maximum score.

Time frame:
Baseline & 12 months
Reported as:
Mean · Change in percentage of total Score
Change From Baseline Short Form 36 (SF-36) Quality of Life Assessment at 12 Months
Change in percentage of total ScoreRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Bodily Pain-4.518 ± 10.0522-3.756 ± 9.9213
General Health-4.290 ± 7.4076-3.301 ± 5.8211
Mental Component Summary-2.282 ± 7.1270-1.061 ± 6.6251
Mental Health-1.725 ± 7.1576-1.570 ± 6.3522
Physical Component Summary-3.952 ± 6.6367-3.403 ± 6.1115
Physical Functioning-2.697 ± 7.4670-1.996 ± 6.6726
Role Emotional-2.928 ± 7.2390-0.747 ± 7.4962
Role Physical-3.421 ± 7.1914-2.793 ± 7.6901
Social Function-4.102 ± 8.4631-2.364 ± 6.3713
Vitality-2.633 ± 7.6406-2.376 ± 7.6968
SecondaryNumber of Patients With Microhematuria at 9 Months Compared to Baseline
Time frame:
9 months
Reported as:
Count of participants · Participants
Number of Patients With Microhematuria at 9 Months Compared to Baseline
ParticipantsRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Number of Patients With Microhematuria at 9 Months Compared to Baseline1017
SecondaryNumber of Patients Receiving Rescue Treatment

Systemic immunosuppressive drugs (including glucocorticoids in some situations ), dialysis, and renal transplantation are considered as rescue medications in this study.

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Patients Receiving Rescue Treatment
ParticipantsRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Number of Patients Receiving Rescue Treatment10
SecondaryProportion of Patients on Dialysis, Undergoing Kidney Transplantation, or With eGFR <15 mL/Min Per 1.73 m2

Looking at number of patients with end stage kidney disease defined as being on dialysis, undergoing kidney transplantation, or having eGFR \<15 mL/min per 1.73 m2

Time frame:
12 months
Reported as:
Count of participants · Participants
Proportion of Patients on Dialysis, Undergoing Kidney Transplantation, or With eGFR <15 mL/Min Per 1.73 m2
ParticipantsRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Proportion of Patients on Dialysis, Undergoing Kidney Transplantation, or With eGFR <15 mL/Min Per 1.73 m220
SecondaryChange From Baseline Cortisol Suppression at 9 Months

Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.

Time frame:
Baseline & 9 months
Reported as:
Mean · ug/day)
Change From Baseline Cortisol Suppression at 9 Months
ug/day)Retreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Change From Baseline Cortisol Suppression at 9 Months-24.122 ± 25.1690-32.126 ± 30.6978
SecondaryChange From Baseline Cortisol Suppression at 12 Months

Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.

Time frame:
Baseline & 12 months
Reported as:
Mean · ug/day
Change From Baseline Cortisol Suppression at 12 Months
ug/dayRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Change From Baseline Cortisol Suppression at 12 Months-7.660 ± 27.4262-11.954 ± 25.8052

Adverse events

Collected over All-Cause Mortality, SAEs and non-serious AEs were assessed from date of first dose of study treatment until 12 months after the first dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Retreatment - Previously Treated With Nefecon in Nef-301 Study0/45 (0%)5/45 (11.1%)32/45 (71.1%)
Delayed Treatment - Previously Treated With Placebo in Nef-301 Study0/74 (0%)5/74 (6.8%)46/74 (62.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
LymphadenopathyBlood and lymphatic system disorders1/450/74
Joint dislocationInjury, poisoning and procedural complications1/450/74
Central nervous system vasculitisNervous system disorders1/450/74
Atrial fibrillationCardiac disorders1/450/74
OsteoarthritisMusculoskeletal and connective tissue disorders1/450/74
HaematuriaRenal and urinary disorders1/450/74
Monoclonal B-cell lymphocytosisBlood and lymphatic system disorders0/451/74
Scapula fractureInjury, poisoning and procedural complications0/451/74
HeadacheNervous system disorders0/451/74
ChorioretinopathyEye disorders0/451/74
Most frequent other events
Showing 10 of 18
Most frequent other events
EventRetreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 Study
Corona virus infectionInfections and infestations12/4513/74
HypertensionVascular disorders8/4512/74
Oedema peripheralGeneral disorders1/4510/74
Muscle spasmsMusculoskeletal and connective tissue disorders6/455/74
Weight increasedInvestigations3/458/74
FatigueGeneral disorders4/452/74
ArthralgiaMusculoskeletal and connective tissue disorders4/453/74
HeadacheNervous system disorders4/453/74
ProteinuriaRenal and urinary disorders4/455/74
AcneSkin and subcutaneous tissue disorders3/456/74

Baseline characteristics

Age, Continuous
Age, Continuous(years)Retreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 StudyTotal
Median46 (29 to 70)47 (25 to 76)47 (25 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Retreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 StudyTotal
Female61925
Male395594
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Retreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 StudyTotal
American Indian or Alaska Native000
Asian9716
Native Hawaiian or Other Pacific Islander000
Black or African American000
White3664100
More than one race000
Unknown or Not Reported033
Region of Enrollment
Region of Enrollment(participants)Retreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 StudyTotal
Argentina639
Czechia21315
United States6511
United Kingdom336
Belarus112
Spain112
Greece358
Canada7714
South Korea246
Sweden123
Turkey022
Belgium437
Finland134
Poland033
Italy213
Australia279
France134
Germany3811
Urine Protein to Creatine Ratio (UPCR)
Urine Protein to Creatine Ratio (UPCR)(g/gram)Retreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 StudyTotal
Geometric mean1.253 (0.859 to 1.796)1.339 (1.000 to 1.881)1.306 (0.935 to 1.881)
Baseline Estimated glomerular filtration rate (eGFR)
Baseline Estimated glomerular filtration rate (eGFR)(ml/min/1.73 m2)Retreatment - Previously Treated With Nefecon in Nef-301 StudyDelayed Treatment - Previously Treated With Placebo in Nef-301 StudyTotal
Geometric mean51.0 (42.0 to 62.0)49.9 (39.9 to 64.9)50.3 (39.9 to 63.5)
08

Study locations

18 sites
  • 13 Investigator sites
    Palo Alto, California 94304, United States
  • 4 Investigator sites
    Buenos Aires, Argentina
  • 6 Investigator sites
    Melbourne, Australia
  • 3 Investigator sites
    Minsk, Belarus
  • 4 Investigator sites
    Brussel, Belgium
  • 7 Investigator sites
    Québec, Canada
  • 6 Investigator sites
    Praha, Czechia
  • 2 Investigator sites
    Jyväskylä, Finland
  • 2 Investigator sites
    Saint-Priest-en-Jarez, France
  • 5 Investigator sites
    Aachen, Germany
  • 5 Investigator sites
    Athens, Greece
  • 2 Investigator sites
    Milano, Italy
  • 4 Investigator sites
    Gyeonggi-do, Korea, Republic of
  • 2 Investigator sites
    Łódź, Poland
  • 4 Investigator sites
    Barcelona, Spain
  • 3 Investigator sites
    Uppsala, Sweden
  • 3 Investigator sites
    Kayseri, Turkey
  • 6 Investigator sites
    Leicester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Feb 2024, 39 months.

Results were first posted in Jan 2025, 10 months after primary completion.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Sep 9, 2020
StartActual
Nov 17, 2020
Primary completionActual
Feb 26, 2024
CompletionActual
Feb 26, 2024
Results first posted
Jan 3, 2025
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04541043
Lead sponsor
Calliditas Therapeutics AB
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Nov 17, 2020
Primary completion
Feb 26, 2024
Completion
Feb 26, 2024
Results posted
Jan 3, 2025
Last update
Feb 10, 2025

Study contacts

Richard Philipson, MD
study director · Calliditas Therapeutics AB

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion